SCHEMBL20257529

SCHEMBL20257529

Cc1cc(Cc2ccc(F)c(Cl)c2)cc(Cl)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 1/20 0.41
SOS1 Q07889 5/20 0.41
CYP3A4 P08684 2/20 0.40
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
PARP1 P09874 2/20 0.37
PIK3CA P42336 1/20 0.37
KDM4E B2RXH2 1/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
P2RX7 Q99572 2/20 0.36
HTR2A P28223 2/20 0.35
SLC6A4 P31645 2/20 0.35
KCNH2 Q12809 2/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
BRD9 Q9H8M2 1/20 0.35
DAO P14920 1/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14397100 0.84 SOS1 (0.47) RAPGEF4SOS1CYP3A4ESR1ESR2
SCHEMBL19002430 0.79 PNMT (0.46) CYP3A4ESR1ESR2CYP2C19HTR2A
SCHEMBL21384033 0.75 SOS1 (0.44) RAPGEF4SOS1CYP3A4PARP1
SCHEMBL29442817 0.75 SOS1 (0.44) RAPGEF4SOS1CYP3A4PARP1
SCHEMBL17971122 0.75 ESR1 (0.54) CYP3A4ESR1ESR2KDM4ECYP2C19
SCHEMBL1043112 0.74 CALM1 (0.48) CYP3A4PARP1PIK3CACYP2C19HIF1A
SCHEMBL15787659 0.74 HTR2A (0.33) RAPGEF4HTR2AMAPT
SCHEMBL19272824 0.73 SLC6A4 (0.41) SOS1CYP3A4PARP1PIK3CACYP2C19
SCHEMBL8137220 0.73 ALDH1A1 (0.39) RAPGEF4SOS1CYP3A4PARP1PIK3CA
SCHEMBL1503218 0.73 PIK3CA (0.45) SOS1CYP3A4PIK3CACYP2C19SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative MEDSHINE DISCOVERY INC. (CN) 2019-03-12 US disclosed
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE MEDSHINE DISCOVERY INC. (CN) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162878-A1 ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE NDUFV1, NDUFV2, MT-ND4 RAPGEF4 4188/4885SOS1 4265/4885CYP3A4 844/4885
US-10227362-B2 Anti-pulmonary tuberculosis nitroimidazole derivative NDUFV1, NDUFV2, MT-ND4 RAPGEF4 4188/4885SOS1 4265/4885CYP3A4 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.